Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.97 · Revenue $0.00 · 8 analysts
Est. EPS $-0.81 · Revenue $0.00 · 9 analysts
Est. EPS $-3.59 · Revenue $12.50M · 10 analysts
Est. EPS $-0.61 · Revenue $0.00 · 6 analysts
EPS $-2.03 · Revenue $0.00
EPS $-2.51 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-97.2M | +3.3% | -4.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-86.0M | -1.1% | -80.6% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -10.3% | -288.1% | +59.6% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 0.75x | -57.9% | +2.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $24.1M | -41.1% | -16.1% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -6.24 vs -6.31 | +1.1% | -0.80 vs -0.97 | +17.9% |
| Revenue Surprise | $0 vs $397.0M | -100.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Ridloff Elena | director | Stock Option | A | 50,740 | $14.54 |
| Aug 6, 2026 | Ridloff Elena | director: | — | — | 0 | — |
| Jul 5, 2026 | Skerjanec Simona | director | Stock Option | A | 25,370 | $14.80 |
| Jul 5, 2026 | Rudick Richard Alan | director | Stock Option | A | 25,370 | $14.80 |
| Jul 5, 2026 | PHILLIPS BARCLAY A | director | Stock Option | A | 25,370 | $14.80 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Daniel Vitt | Co-Founder & Director | USD 1,126,508 | — | 1968 | Active |
Erik Lundgren | Chief Executive Officer & Director | USD 1,126,508 | Male | 1978 | Active |
Michael A. Panzara | Chief Medical Officer | USD 809,825 | — | 1967 | Active |
Jason Tardio | Chief Operating Officer & President | USD 751,700 | Male | 1977 | Active |
Glenn Whaley | Chief Financial Officer | USD 682,250 | Male | 1968 | Active |
Hella Kohlhof | Co-Founder & Chief Scientific Officer | — | — | 1973 | Active |
Jessica Breu | Vice President of Investor Relations & Communications | — | Female | — | Active |
Patrick Walsh | Chief Business Officer | — | Male | 1983 | Active |
Inderpal Singh | General Counsel | — | Male | 1966 | Active |
Werner Gladdines | Chief Development Officer | — | Male | 1979 | Active |
Shore Capital has reiterated its sell recommendation on HSBC Holdings PLC (LSE:HSBA, NYSE:HSBC), warning the shares' punchy valuation more than reflects the...
Palo Alto Networks Inc (NYSE:PANW, XETRA:5AP) shares fell 10% Wednesday even after the cybersecurity company beat expectations across key fourth-quarter...
Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will feature Immunic management, including CEO Erik Lundgren, chief medical officer Michael Panzara, chief scientific officer Hella Kohlhof and president and chief operating officer Jason Tardio.
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual research and development (R&D) day focused on relapsing multiple sclerosis (MS) on Wednesday, September 9, 2026, at 11:00 am ET.
– New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for Potential NDA Submission and Commercialization – NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Chitrang Davé as Chief Data and Digital Officer (CDDO), effective today.
